ArticleClinical and experimental medicine2018
Droplet digital PCR detects high rate of TP53 R249S mutants in cell-free DNA of middle African patients with hepatocellular carcinoma.
Article in Clinical and experimental medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- Pooled it
- Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: A Systematic Review.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2020Pooled it
- Primary liver cancer at tertiary healthcare facility in Guinea: a cross-sectional study.BMC gastroenterology · 2026Article
- Systematic Review of Methods for Measuring Circulating Cell-Free DNA in Plasma of Healthy Individuals.Diagnostics (Basel, Switzerland) · 2026Review
- Novel biomarkers for monitoring and management of hepatocellular carcinoma.Cancer cell international · 2024Review
- Review
- Exosomal DNA: Role in Reflecting Tumor Genetic Heterogeneity, Diagnosis, and Disease Monitoring.Cancers · 2023Review
- Review
- Cell-free DNA approaches for cancer early detection and interception.Journal for immunotherapy of cancer · 2023Review
- First Molecular Characterization of Chronic Hepatitis B Carriers in Timbuktu, Mali.Diagnostics (Basel, Switzerland) · 2023Article
- Review
- Assessments of TP53 and CTNNB1 gene hotspot mutations in circulating tumour DNA of hepatitis B virus-induced hepatocellular carcinoma.Frontiers in genetics · 2023Article
- Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives.Cancers · 2021Review
- Using cell-free DNA for HCC surveillance and prognosis.JHEP reports : innovation in hepatology · 2021Review
- Review
- Current status of ctDNA in precision oncology for hepatocellular carcinoma.Journal of experimental & clinical cancer research : CR · 2021Review
- Clinical Application Value of Circulating Cell-free DNA in Hepatocellular Carcinoma.Frontiers in molecular biosciences · 2021Review
- Hepatitis B virus preS2Δ38-55 variants: A newly identified risk factor for hepatocellular carcinoma.JHEP reports : innovation in hepatology · 2020Article
- Prospects and challenges of circulating tumor DNA in precision medicine of hepatocellular carcinoma.Clinical and experimental medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is still a major killing malignancy in sub-Saharan Africa. Lifelong intoxication with aflatoxin B1 is considered as one of the primary causes of this situation. The role of aflatoxin in HCC from a given population is commonly estimated through the prevalence of R249S mutation of TP53, a hallmark for previous exposure to the mycotoxin. However, the role of AFB1 is barely known in large part of Africa. We conducted a survey on circulating cell-free DNA from 149 patients with HCC and 213 control subjects with and without liver diseases from Cameroon and Central African Republic using droplet digital PCR technique. We observed a mutation prevalence of 24.8% (n = 37/149) in patients with tumor and 5.6% (n = 12/213) in controls (P = 2.2E-07). Patients with mutations usually displayed significantly increased circulating alpha-fetoprotein (AFP) values, high hepatitis B virus (HBV) DNA loads as well as worsened values of blood cells count. Interestingly, the fraction of droplets positive for R249S was significantly larger in patients with liver cancer (15.3 ± 3.7%) than in controls (0.5 ± 0.3%, P = 7.1E-04). Our survey indicates that AFB1 is instrumental for HCC development in Middle Africa and that droplet digital PCR might be used in the region both to diagnose HCC and to conduct public health surveys on populations at risk of chronic aflatoxin intoxication.
Indexed as
Identifiers
29749584What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.